Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=56 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Phase 2 N=94 A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Phase 2 N=215 Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Colorectal Cancer
Primary: Progression Free Survival — 5.8; 7.2; 7.8 Months
Phase 2 N=28 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) — 0; 1; 0; 4 Participants
Phase 2 N=63 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Median Time for Progression Free Survival — 15.8 Months
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Phase 2 N=338 Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Phase 2 N=171 A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Colorectal Neoplasms
Primary: Progression Free Survival (PFS) — 5.72; 6.87; 7.59; 6.44 Months — p=0.8268
Phase 3 N=1,076 Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 8.6; 8.2 Months
Phase 2 N=36 Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Colon Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 55 percentage of patients
Phase 2 N=36 Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Adenocarcinoma · RAS Wild Type · Stage IV Colorectal Cancer AJCC v7
Primary: Progression-Free Survival (PFS) — 9.7; 5.5 months — p=0.7609
Phase 2 N=181 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=16 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Progression Free Survival (PFS) — 255.921 days to progression
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=83 Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
Phase 2 N=136 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Colorectal Cancer
Primary: Progression-free Survival — 5.98; 7.03; 9.20 months
Phase 2 N=131 ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal…
Phase 2 N=80 A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 2 N=47 RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Colorectal Cancer
Primary: Progression Free Survival at Six Months — 87 percentage of participants
Phase 2 N=50 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
Colorectal Adenocarcinoma
Primary: Overall Response — 0 percentage of participants
Phase 3 N=1,614 First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Colorectal Cancer
Primary: Progression Free Survival — 9.9; 10.3 Months
Phase 2 N=3 Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I) — NA
Phase 3 N=760 Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months